Brooks Laboratories Intrinsic Value
BROOKS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹222.63 | ₹178.10 - ₹267.16 | +200.0% | EPS: ₹10.84, Sector P/E: 22x |
| Book Value Method | asset | ₹65.33 | ₹58.80 - ₹71.86 | -12.0% | Book Value/Share: ₹32.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹80.00 | ₹72.00 - ₹88.00 | +7.8% | Revenue/Share: ₹40.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹117.57 | ₹105.81 - ₹129.33 | +58.4% | EBITDA: ₹36.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹29.68 | ₹23.74 - ₹35.62 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹69.38 | ₹62.44 - ₹76.32 | -6.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹167.48 | ₹150.73 - ₹184.23 | +125.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹148.42 | ₹133.58 - ₹163.26 | +100.0% | ROE: 32.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹65.33 | ₹58.80 - ₹71.86 | -12.0% | EPS: ₹10.84, BVPS: ₹32.67 |
Want to compare with current market value? Check BROOKS share price latest .
Valuation Comparison Chart
BROOKS Intrinsic Value Analysis
What is the intrinsic value of BROOKS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Brooks Laboratories (BROOKS) is ₹80.00 (median value). With the current market price of ₹74.21, this represents a +7.8% variance from our estimated fair value.
The valuation range spans from ₹29.68 to ₹222.63, indicating ₹29.68 - ₹222.63.
Is BROOKS undervalued or overvalued?
Based on our multi-method analysis, Brooks Laboratories (BROOKS) appears to be trading near calculated value by approximately 7.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.27 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 32.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.97x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Brooks Laboratories
Additional stock information and data for BROOKS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-15 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-37 Cr | ₹-50 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |